$4.06
N/A
Last update: Nov 11, 10:33 AM
Artiva Biotherapeutics Inc
ARTVNASDAQ
Artiva Biotherapeutics rose 17.5% from $3.59 to $4.22, ahead of the S&P 500's +9.8%. Its worst day was Oct 27 (−30.7%), and its low came Dec 10 at $3.07.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.88 missed the $-0.85 estimate on $0.00 revenue.
+10.9% · S&P 500 +0.1%
Artiva Biotherapeutics closed at its lowest level of the year, 14.5% below where the year started.
Story events cover the past 12 months · Times ET
−1.6% · S&P 500 +0.7%
EPS of $-0.84 missed the $-0.83 estimate on $0.00 revenue.
+6.5% · S&P 500 −0.2%
Artiva Biotherapeutics closed at its highest level of the year, 273.0% above where the year started.
+6.7% · S&P 500 −0.2%
EPS of $-0.95 missed the $-0.85 estimate on $0.00 revenue.
−13.0% · S&P 500 +0.8%
EPS of $-0.63 beat the $-0.64 estimate on $0.00 revenue.
−2.7% · S&P 500 +0.6%
Artiva Biotherapeutics shares fell 30.7%, while the S&P 500 rose 0.6%.
−30.7%, the year's worst day · S&P 500 +0.6%
Where it ended: a close of $4.22 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.54).
Nothing in the past 12 months.
All ARTV dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ARTV and SPY from Benzinga historical bars. Not investment advice.
